Graham Capital Management L.P. Acquires 3,483 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Graham Capital Management L.P. grew its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 25.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 17,428 shares of the company’s stock after purchasing an additional 3,483 shares during the quarter. Graham Capital Management L.P.’s holdings in Twist Bioscience were worth $810,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in TWST. Arizona State Retirement System lifted its stake in shares of Twist Bioscience by 1.3% in the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock worth $789,000 after buying an additional 219 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares during the last quarter. Hillsdale Investment Management Inc. lifted its stake in shares of Twist Bioscience by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock worth $3,625,000 after buying an additional 300 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of Twist Bioscience by 1.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company’s stock worth $1,107,000 after buying an additional 403 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Twist Bioscience by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company’s stock worth $283,000 after buying an additional 443 shares during the last quarter.

Insider Activity

In other news, SVP Paula Green sold 918 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the transaction, the senior vice president now owns 130,912 shares in the company, valued at approximately $5,355,609.92. This represents a 0.70% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the transaction, the chief executive officer now owns 662,692 shares of the company’s stock, valued at approximately $27,110,729.72. This represents a 0.36% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,991 shares of company stock worth $742,654. 3.01% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TWST shares. Guggenheim restated a “buy” rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group reduced their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Robert W. Baird reduced their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Finally, Barclays cut their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.40.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $32.29 on Wednesday. The stock has a market cap of $1.93 billion, a P/E ratio of -9.55 and a beta of 2.54. Twist Bioscience Co. has a one year low of $30.72 and a one year high of $60.90. The company has a fifty day moving average price of $38.31 and a 200 day moving average price of $43.56. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.